Did AvePoint’s (AVPT) Dual Russell 2000 Defensive Additions Just Recast Its Investment Narrative?

June 29, 2026

Simply Wall St

Reviewed by Sasha Jovanovic

AvePoint, Inc. (NasdaqGS: AVPT) was recently added to both the Russell 2000 Defensive Index and the Russell 2000 Growth-Defensive Index, marking its inclusion in two widely tracked U.S. small-cap benchmarks.
This dual index inclusion can increase AvePoint’s visibility with institutional investors and passive funds, potentially boosting liquidity and reinforcing its profile as a growth-oriented yet relatively defensive software name.
We’ll now examine how AvePoint’s addition to the Russell 2000 Defensive and Growth-Defensive indices could influence its broader investment narrative.

Uncover the next big thing with 21 elite penny stocks that balance risk and reward.

AvePoint Investment Narrative Recap

To own AvePoint, you need to believe its governance and data protection platform can stay essential as AI and multi-cloud adoption expand, while it manages dependence on Microsoft and maintains healthy margins. The Russell 2000 Defensive and Growth-Defensive additions may support trading liquidity and awareness, but they do not materially change the near term catalysts around AI governance uptake or the key risk of platform and competitive pressure from larger cloud vendors.

The recent AvePoint Confidence Platform enhancements, including broader backup coverage across Microsoft, Google and other SaaS and IaaS sources, tie directly into the growth story that the index inclusion highlights. They speak to AvePoint’s push beyond core Microsoft 365 into multi-cloud governance and resilience, which is central to the potential revenue diversification investors are watching and to whether the business can offset risks from heavy reliance on a single ecosystem.

Yet, beneath the appeal of index inclusion, investors should be aware of how AvePoint’s dependence on Microsoft and rising competition could...

Read the full narrative on AvePoint (it's free!)

AvePoint's narrative projects $795.8 million revenue and $90.4 million earnings by 2029. This requires 21.5% yearly revenue growth and roughly a $43.8 million earnings increase from $46.6 million today.

Uncover how AvePoint's forecasts yield a $16.12 fair value, a 48% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already modeling revenue near US$721.3 million and earnings of about US$121.2 million by 2028, so if you believe AvePoint’s Russell index additions accelerate its AI and multi SaaS governance ambitions faster than consensus, your view could sit much closer to that bullish scenario than to the more cautious narrative around Microsoft dependence and slower multi cloud expansion.

Explore 3 other fair value estimates on AvePoint - why the stock might be worth less than half the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

A great starting point for your AvePoint research is our analysis highlighting 3 key rewards that could impact your investment decision.
Our free AvePoint research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate AvePoint's overall financial health at a glance.

Ready For A Different Approach?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

Outshine the giants: these 15 early-stage AI stocks could fund your retirement.
Find 44 companies with promising cash flow potential yet trading below their fair value.
AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

mitchell_lawler

A landmark settlement is meant to punish Meta (META). If the 1998 tobacco deal is any guide, it might protect it.

118

zoe_vi5fn1d

Any moat with an opt-out clause for your competitors is just a fence around your own garden.

connor_iwn1g1d

Worth looking at what previous legal action actually did to Meta rather than reaching for tobacco. The FTC's record five billion dollar privacy fine in 2019 was met with the stock rising, because it came in below fears and removed an open question. GDPR was designed to constrain large platforms and increased their share of the European ad market, because compliance cost fell hardest on small intermediaries. The FTC's antitrust case, the one that could genuinely have broken the company up, was decided in Meta's favour last November. The only thing that ever meaningfully hurt the business was Apple changing a tracking default, and Meta out-spent that too, while the ad-tech firms that could not afford to rebuild disappeared. The pattern is not that Meta survives regulation. It is that regulation keeps costing its smaller competitors more.